CN104797247A - 用于治疗由psma表达细胞引起的疾病的共轭物 - Google Patents

用于治疗由psma表达细胞引起的疾病的共轭物 Download PDF

Info

Publication number
CN104797247A
CN104797247A CN201380059438.0A CN201380059438A CN104797247A CN 104797247 A CN104797247 A CN 104797247A CN 201380059438 A CN201380059438 A CN 201380059438A CN 104797247 A CN104797247 A CN 104797247A
Authority
CN
China
Prior art keywords
conjugate
diradical
linker
conjugates
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201380059438.0A
Other languages
English (en)
Chinese (zh)
Inventor
I·R·弗拉霍夫
J·A·雷迪
艾丽西娅·布洛姆菲尔德
瑞恩·多顿
梅丽莎·尼尔森
玛丽莲·韦特泽尔
C·P·利蒙
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Endocyte Inc
Original Assignee
Endocyte Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endocyte Inc filed Critical Endocyte Inc
Priority to CN201810002493.0A priority Critical patent/CN108042811A/zh
Publication of CN104797247A publication Critical patent/CN104797247A/zh
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06104—Dipeptides with the first amino acid being acidic
    • C07K5/06113—Asp- or Asn-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201380059438.0A 2012-11-15 2013-11-14 用于治疗由psma表达细胞引起的疾病的共轭物 Withdrawn CN104797247A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810002493.0A CN108042811A (zh) 2012-11-15 2013-11-14 用于治疗由psma表达细胞引起的疾病的共轭物

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261726991P 2012-11-15 2012-11-15
US61/726,991 2012-11-15
US201361788382P 2013-03-15 2013-03-15
US61/788,382 2013-03-15
US201361875971P 2013-09-10 2013-09-10
US61/875,971 2013-09-10
PCT/US2013/070007 WO2014078484A1 (en) 2012-11-15 2013-11-14 Conjugates for treating diseases caused by psma expressing cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201810002493.0A Division CN108042811A (zh) 2012-11-15 2013-11-14 用于治疗由psma表达细胞引起的疾病的共轭物

Publications (1)

Publication Number Publication Date
CN104797247A true CN104797247A (zh) 2015-07-22

Family

ID=50731670

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201810002493.0A Pending CN108042811A (zh) 2012-11-15 2013-11-14 用于治疗由psma表达细胞引起的疾病的共轭物
CN201380059438.0A Withdrawn CN104797247A (zh) 2012-11-15 2013-11-14 用于治疗由psma表达细胞引起的疾病的共轭物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201810002493.0A Pending CN108042811A (zh) 2012-11-15 2013-11-14 用于治疗由psma表达细胞引起的疾病的共轭物

Country Status (17)

Country Link
US (17) US9636413B2 (enExample)
EP (3) EP3875082A1 (enExample)
JP (4) JP6892218B2 (enExample)
KR (5) KR102575825B1 (enExample)
CN (2) CN108042811A (enExample)
AU (7) AU2013344778C1 (enExample)
BR (1) BR112015011118B1 (enExample)
CA (2) CA2891476C (enExample)
EA (2) EA201590783A1 (enExample)
HK (2) HK1211493A1 (enExample)
IL (1) IL238784A0 (enExample)
MX (2) MX2015006109A (enExample)
MY (1) MY171561A (enExample)
SG (2) SG10201706618UA (enExample)
TW (1) TWI674111B (enExample)
WO (1) WO2014078484A1 (enExample)
ZA (1) ZA201504234B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109312004A (zh) * 2016-06-22 2019-02-05 德克斯特克医疗公司 包含赖氨酸-脲-谷氨酸药效团的改性右旋糖酐缀合物
CN112004812A (zh) * 2018-03-30 2020-11-27 未来化学株式会社 用于前列腺癌的诊断和治疗的psma靶向的放射性药物

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2149952A1 (en) 1994-06-30 1995-12-31 Robert M. Wallace Monolayer coating using molecular recognition for micro-mechanical devices
US5652671A (en) 1994-06-30 1997-07-29 Texas Instruments Incorporated Hinge for micro-mechanical device
CN101098854B (zh) 2004-07-23 2012-12-05 恩多塞特公司 二价连接体及其轭合物
NZ599239A (en) 2007-03-14 2013-10-25 Endocyte Inc Binding ligand linked drug delivery conjugates of tubulysins
US9138484B2 (en) 2007-06-25 2015-09-22 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
PL2187965T3 (pl) 2007-08-17 2020-05-18 Purdue Research Foundation Koniugaty wiążący psma ligand-łącznik i sposoby ich zastosowania
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
WO2013126797A1 (en) 2012-02-24 2013-08-29 Purdue Research Foundation Cholecystokinin b receptor targeting for imaging and therapy
US20140080175A1 (en) 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
US9662402B2 (en) 2012-10-16 2017-05-30 Endocyte, Inc. Drug delivery conjugates containing unnatural amino acids and methods for using
KR102575825B1 (ko) 2012-11-15 2023-09-06 엔도사이트, 인코포레이티드 Psma 발현 세포에 의해 야기되는 질병을 치료하기 위한 컨쥬게이트
MY194484A (en) 2013-10-18 2022-11-30 Deutsches Krebsforsch Labeled Inhibitors of Prostate Specific Membrane Antigen (PSMA), Their use as Imaging Agents and Pharmaceutical Agents for the Treatment of Prostate Cancer
MX2016006219A (es) 2013-11-14 2016-10-28 Endocyte Inc Compuestos para tomografia por emision de positrones.
JP6664329B2 (ja) * 2014-01-28 2020-03-13 トゥーベ・ファルマシューティカルズ・ゲー・エム・ベー・ハー コンジュゲーションのための新規な細胞毒性チューブリシン化合物
US10278991B2 (en) 2014-05-14 2019-05-07 Targimmune Therapeutics Ag Polyethyleneimine polyethyleneglycol vectors
US10077287B2 (en) 2014-11-10 2018-09-18 Bristol-Myers Squibb Company Tubulysin analogs and methods of making and use
WO2016089879A1 (en) * 2014-12-01 2016-06-09 Endocyte, Inc. Conjugates of garftase inhibitors
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
EP3265471A1 (en) * 2015-03-01 2018-01-10 Endocyte, Inc. Methods of treating cancer with a psma ligand-tubulysin compound
CN107847609A (zh) * 2015-03-13 2018-03-27 恩多塞特公司 用于治疗疾病的缀合物
KR101639599B1 (ko) * 2015-11-09 2016-07-14 서울대학교산학협력단 펩타이드 싸이오우레아 유도체, 이를 포함하는 방사성 동위원소 표지 화합물 및 이를 유효 성분으로 함유하는 전립선암 치료 또는 진단용 약학적 조성물
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
US11229708B2 (en) 2015-12-04 2022-01-25 Seagen Inc. Conjugates of quaternized tubulysin compounds
US10688200B2 (en) * 2015-12-31 2020-06-23 Five Eleven Pharma Inc. Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy
US20170296679A1 (en) 2016-04-18 2017-10-19 Intuitive Surgical Operations, Inc. Compositions of Near IR Closed Chain, Sulfo-Cyanine Dyes and Prostate Specific Membrane Antigen Ligands
WO2017205447A1 (en) * 2016-05-24 2017-11-30 Endocyte, Inc. Methods of treating cancer with a psma ligand-tubulysin compound
EP3484529A4 (en) 2016-07-14 2020-04-08 William Marsh Rice University MECHANICAL OPENING OF LIPID DOUBLE LAYERS THROUGH MOLECULAR NANO MACHINES
KR102724828B1 (ko) 2017-09-22 2024-10-31 하이델베르크 파마 리서치 게엠베하 신규한 psma-표적화 아마니틴 결합체
MX2020006112A (es) 2017-12-13 2020-08-24 Sciencons AS Complejo que comprende un compuesto orientado a psma vinculado a un radionucleido de plomo o torio.
KR20210003135A (ko) 2018-04-17 2021-01-11 엔도사이트, 인코포레이티드 암의 치료 방법
US20210323985A1 (en) * 2018-09-21 2021-10-21 Endocyte, Inc. Shielding agents and their use
SG11202108182RA (en) * 2019-01-30 2021-08-30 Coherent Biopharma Suzhou Limited Bi-ligand drug conjugate and use thereof
WO2020210909A1 (en) 2019-04-17 2020-10-22 Provincial Health Services Authority Novel radiolabelled compounds for diagnosis or treatment of prostate-specific membrane antigen-expressing cancer
US20220125959A1 (en) * 2019-04-26 2022-04-28 Five Eleven Pharma Inc. Prostate-specific membrane antigen (psma) inhibitors as diagnostic and radionuclide therapeutic agents
WO2020236808A1 (en) 2019-05-20 2020-11-26 Endocyte, Inc. Methods for preparing psma conjugates
KR20220024595A (ko) 2019-06-21 2022-03-03 프로빈셜 헬스 서비시즈 오쏘리티 전립선-특이적 막 항원을 표적으로 하는 방사성표지 화합물
DE102019135564B4 (de) * 2019-12-20 2022-05-19 Johannes-Gutenberg-Universität Mainz Verbindung für Smart-Drug-Delivery und pharmazeutisches Kit für duale nuklearmedizinisch-cytotoxische Theranostik
EP4138811A4 (en) * 2020-04-24 2024-03-06 Radiomedix Inc. COMPOSITION, KIT AND METHOD FOR THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER
CN120676964A (zh) 2022-11-17 2025-09-19 H-G·勒珍 在肿瘤微环境中可裂解的小分子-药物缀合物
JP2025534939A (ja) 2023-07-31 2025-10-22 キュリウム ユーエス エルエルシー ［１７７ｌｕ］ルテチウム－ｐｓｍａ ｉ＆ｔ組成物及び線量測定、キット、それを作製する方法、並びにそれを使用する方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008121949A1 (en) * 2007-03-30 2008-10-09 Bind Biosciences, Inc. Cancer cell targeting using nanoparticles

Family Cites Families (226)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4713249A (en) 1981-11-12 1987-12-15 Schroeder Ulf Crystallized carbohydrate matrix for biologically active substances, a process of preparing said matrix, and the use thereof
DE116208T1 (de) 1982-12-07 1985-02-28 Kyowa Hakko Kogyo Co., Ltd., Tokio/Tokyo Mitomycin-analoge.
JPS60255789A (ja) 1984-06-01 1985-12-17 Kyowa Hakko Kogyo Co Ltd マイトマイシン誘導体，その製造法および抗腫瘍剤
US5266333A (en) 1985-03-06 1993-11-30 American Cyanamid Company Water dispersible and water soluble carbohydrate polymer compositions for parenteral administration of growth hormone
US5103018A (en) 1986-08-26 1992-04-07 Kyowa Hakko Kogyo Kabushiki Kaisha Mitomycin derivatives
KR910009284A (ko) 1989-11-13 1991-06-28 원본미기재 인체 종양 세포 항원에 특이적인 키메라형 생쥐-인체 a10 항체
US5627165A (en) 1990-06-13 1997-05-06 Drug Innovation & Design, Inc. Phosphorous prodrugs and therapeutic delivery systems using same
AU653565B2 (en) 1990-12-21 1994-10-06 Nikken Corporation Raw sewage disposal apparatus and prefab for accomodating the same
US6291196B1 (en) 1992-01-31 2001-09-18 Research Corporation Technologies, Inc. Melanoma and prostate cancer specific antibodies for immunodetection and immunotherapy
US7070782B1 (en) 1992-11-05 2006-07-04 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen
US5674977A (en) 1993-02-05 1997-10-07 The Ontario Cancer Institute Branched synthetic peptide conjugate
US6569432B1 (en) 1995-02-24 2003-05-27 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen and uses thereof
JP3538221B2 (ja) 1993-11-19 2004-06-14 富士写真フイルム株式会社 定着濃厚液およびそれを用いたハロゲン化銀写真感光材料の処理方法
US5866679A (en) 1994-06-28 1999-02-02 Merck & Co., Inc. Peptides
US6946133B1 (en) 1996-03-20 2005-09-20 The United States Of America As Represented By The Department Of Health And Human Services Prostate specific antigen oligo-epitope peptide
PT907379E (pt) 1996-04-01 2004-09-30 Epix Medical Inc Agentes de contraste bioactivados para imagiologia de diagnostico
US5962237A (en) 1996-04-05 1999-10-05 The Johns Hopkins University School Of Medicine Method of enriching rare cells
US5795877A (en) 1996-12-31 1998-08-18 Guilford Pharmaceuticals Inc. Inhibitors of NAALADase enzyme activity
US5863536A (en) 1996-12-31 1999-01-26 Guilford Pharmaceuticals Inc. Phosphoramidate derivatives
US5902817A (en) 1997-04-09 1999-05-11 Guilford Pharmaceuticals Inc. Certain sulfoxide and sulfone derivatives
US5672592A (en) 1996-06-17 1997-09-30 Guilford Pharmaceuticals Inc. Certain phosphonomethyl-pentanedioic acid derivatives thereof
US6054444A (en) 1997-04-24 2000-04-25 Guilford Pharmaceuticals Inc. Phosphonic acid derivatives
US5998362A (en) 1996-09-12 1999-12-07 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US6368598B1 (en) 1996-09-16 2002-04-09 Jcrt Radiation Oncology Support Services, Inc. Drug complex for treatment of metastatic prostate cancer
US5962521A (en) 1997-04-04 1999-10-05 Guilford Pharmaceuticals Inc. Hydroxamic acid derivatives
US6177404B1 (en) 1996-10-15 2001-01-23 Merck & Co., Inc. Conjugates useful in the treatment of benign prostatic hyperplasia
US5948750A (en) 1996-10-30 1999-09-07 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
AU7019498A (en) 1997-04-10 1998-10-30 Diagnocure Inc. Pca3, pca3 genes, and methods of use
US6127333A (en) 1997-07-10 2000-10-03 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US6391305B1 (en) 1997-09-10 2002-05-21 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US20020115596A1 (en) 1997-10-27 2002-08-22 Merk & Co., Inc. Conjugates useful in the treatment of prostate cancer
ID24735A (id) 1997-12-02 2000-08-03 Merck & Co Ltd Konjugat-konjugat yang berguna pada pengobatan kanker prostat
US20040081659A1 (en) 1997-12-02 2004-04-29 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
ZA9810974B (en) 1997-12-02 1999-06-03 Merck & Co Inc Conjugates useful in the treatment of prostate cancer
AU2896399A (en) 1998-03-03 1999-09-20 Exact Sciences Corporation Purification and detection processes using reversible affinity electrophoresis
US20020103136A1 (en) 1998-03-05 2002-08-01 Dong-Mei Feng Conjugates useful in the treatment of prostate cancer
US6232287B1 (en) 1998-03-13 2001-05-15 The Burnham Institute Molecules that home to various selected organs or tissues
US6093382A (en) 1998-05-16 2000-07-25 Bracco Research Usa Inc. Metal complexes derivatized with folate for use in diagnostic and therapeutic applications
US6833438B1 (en) 1999-06-01 2004-12-21 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
DE69941187D1 (de) 1998-06-01 2009-09-10 Agensys Inc Serpentintransmembranantigene exprimiert in menschlichem krebs und deren verwendungen
US20070020327A1 (en) 1998-11-10 2007-01-25 John Fikes Inducing cellular immune responses to prostate cancer antigens using peptide and nucleic acid compositions
US6174858B1 (en) 1998-11-17 2001-01-16 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US20030207808A1 (en) 1999-02-18 2003-11-06 Kinneret Savitzky Novel nucleic acid and amino acid sequences
AU4063600A (en) 1999-04-05 2000-10-23 Merck & Co., Inc. A method of treating cancer
CA2367787C (en) 1999-04-28 2011-07-26 Alan P. Kozikowski Ligands for metabotropic glutamate receptors
US6528499B1 (en) 2000-04-27 2003-03-04 Georgetown University Ligands for metabotropic glutamate receptors and inhibitors of NAALADase
AUPQ014799A0 (en) 1999-05-04 1999-05-27 Access Pharmaceuticals Australia Pty Limited Amplification of folate-mediated targeting to tumor cells using polymers
US7166573B1 (en) 1999-05-28 2007-01-23 Ludwig Institute For Cancer Research Breast, gastric and prostate cancer associated antigens and uses therefor
US20040146516A1 (en) 1999-06-17 2004-07-29 Utah Ventures Ii L.P. Lumen-exposed molecules and methods for targeted delivery
US7361338B2 (en) 1999-10-05 2008-04-22 Agensys, Inc. Methods to inhibit growth of prostate cancer cells
US6692724B1 (en) 1999-10-25 2004-02-17 Board Of Regents, The University Of Texas System Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
US6428785B1 (en) 1999-10-28 2002-08-06 Immunolytics Inc. Method and composition for treating prostate cancer
CA2391534A1 (en) 1999-11-15 2001-05-25 Drug Innovation & Design, Inc. Selective cellular targeting: multifunctional delivery vehicles
AU5697001A (en) 2000-03-31 2001-10-15 Purdue Research Foundation Method of treatment using ligand-immunogen conjugates
US20030072794A1 (en) 2000-06-09 2003-04-17 Teni Boulikas Encapsulation of plasmid DNA (lipogenes™) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes
JP4176466B2 (ja) 2000-10-16 2008-11-05 ギリード・サイエンシズ・インコーポレーテッド 前立腺特異的膜抗原に対する核酸リガンド
US20020132983A1 (en) 2000-11-30 2002-09-19 Junghans Richard P. Antibodies as chimeric effector cell receptors against tumor antigens
US7468354B2 (en) 2000-12-01 2008-12-23 Genspera, Inc. Tissue specific prodrugs
EP1390081A2 (en) 2001-01-08 2004-02-25 Neorx Corporation Therapeutic and diagnostic compounds, compositions, and methods
DE60214134T2 (de) 2001-02-07 2007-07-19 Beth Israel Deaconess Medical Center, Boston Modifizierte psma-liganden und deren verwendung
WO2002074345A2 (en) 2001-03-16 2002-09-26 Johns Hopkins University School Of Medicine Immune modulation by transduced hematopoietic stem cells expressing antigens and antigen-presenting cell regulatory molecules
US7875612B2 (en) 2001-04-24 2011-01-25 Purdue Research Foundation Folate mimetics and folate-receptor binding conjugates thereof
RU2316349C2 (ru) 2001-05-02 2008-02-10 Пердью Рисерч Фаундейшн Лечение и диагностика заболеваний, опосредованных макрофагами
US7109165B2 (en) 2001-05-18 2006-09-19 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US7514078B2 (en) 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
IL158969A0 (en) 2001-06-01 2004-05-12 Cornell Res Foundation Inc Modified antibodies to prostate-specific membrane antigen and uses thereof
US20040018203A1 (en) 2001-06-08 2004-01-29 Ira Pastan Pegylation of linkers improves antitumor activity and reduces toxicity of immunoconjugates
AU2002315411A1 (en) 2001-06-21 2003-01-08 Glycotech Corporation Detection and treatment of prostate cancer
WO2003000201A2 (en) 2001-06-25 2003-01-03 Drug Innovation & Design, Incorporated Exponential pattern recognition based cellular targeting, compositions, methods and anticancer applications
US7755757B2 (en) 2007-02-14 2010-07-13 Chemimage Corporation Distinguishing between renal oncocytoma and chromophobe renal cell carcinoma using raman molecular imaging
US7893223B2 (en) * 2001-07-17 2011-02-22 Bracco Imaging S.P.A. Multidentate AZA ligands able to complex metal ions and the use thereof in diagnostics and therapy
US7282476B2 (en) 2001-08-24 2007-10-16 University Of Victoria Innovation And Development Corporation Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer
US7192586B2 (en) 2001-09-20 2007-03-20 Cornell Research Foundation, Inc. Methods and compositions for treating or preventing skin disorders using binding agents specific for prostate specific membrane antigen
US20030232760A1 (en) 2001-09-21 2003-12-18 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
EP1434603B1 (en) 2001-09-28 2009-12-16 Purdue Research Foundation Method of treatment using ligand-immunogen conjugates
US20030215456A1 (en) 2001-10-02 2003-11-20 Sui-Long Yao Method of treating cancer
US20030133927A1 (en) 2001-10-10 2003-07-17 Defeo-Jones Deborah Conjugates useful in the treatment of prostate cancer
US20040058857A1 (en) 2001-11-29 2004-03-25 Siu-Long Yao Method of treating cancer
US20070031438A1 (en) 2001-12-10 2007-02-08 Junghans Richard P Antibodies as chimeric effector cell receptors against tumor antigens
CA2473289C (en) * 2002-01-10 2014-07-29 The Johns Hopkins University Asymmetric urea compounds useful as naaladase and psma imaging agents
US7344700B2 (en) 2002-02-28 2008-03-18 University Of Tennessee Research Corporation Radiolabeled selective androgen receptor modulators and their use in prostate cancer imaging and therapy
US7794929B2 (en) 2002-03-07 2010-09-14 The Johns Hopkins University School Of Medicine Genomic screen for epigenetically silenced genes associated with cancer
US7534580B2 (en) 2002-05-01 2009-05-19 Ambrilia Biopharma Inc. PSP94 diagnostic reagents and assays
WO2003092742A1 (en) 2002-05-06 2003-11-13 Endocyte, Inc. Vitamin-targeted imaging agents
DE60326833D1 (de) 2002-05-15 2009-05-07 Endocyte Inc Vitamin-mitomycin-konjugate
US7767803B2 (en) 2002-06-18 2010-08-03 Archemix Corp. Stabilized aptamers to PSMA and their use as prostate cancer therapeutics
AU2003266233A1 (en) 2002-07-09 2004-01-23 Morphochem Aktiengesellschaft Fur Kombinatorische Chemie Novel tubulysin analogues
AR040956A1 (es) 2002-07-31 2005-04-27 Schering Ag Nuevos conjugados de efectores, procedimientos para su preparacion y su uso farmaceutico
JP4741838B2 (ja) 2002-07-31 2011-08-10 シアトル ジェネティクス，インコーポレーテッド 癌、自己免疫疾患または感染症を治療するための薬物結合体およびその使用
US7749968B2 (en) 2002-08-05 2010-07-06 The Johns Hopkins University Peptides for targeting the prostate specific membrane antigen
WO2004015086A2 (en) 2002-08-08 2004-02-19 Johns Hopkins University Enhancement of adenoviral oncolytic activity in prostate cells by modification of the e1a gene product
DE10254439A1 (de) 2002-11-21 2004-06-03 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Tubulysine, Herstellungsverfahren und Tubulysin-Mittel
US8487128B2 (en) 2002-11-26 2013-07-16 Chs Pharma, Inc. Protection of normal cells
WO2004058158A2 (en) 2002-12-20 2004-07-15 The Johns Hopkins University Treatment of metastatic cancer with the b-subunit of shiga toxin
US7226577B2 (en) 2003-01-13 2007-06-05 Bracco Imaging, S. P. A. Gastrin releasing peptide compounds
US20080008649A1 (en) 2003-01-13 2008-01-10 Bracco Imaging S.P.A. Gastrin Releasing Peptide Compounds
AR042942A1 (es) 2003-01-27 2005-07-06 Endocyte Inc Conjugados de administracion de drogas de union de receptores de vitaminas
US7811564B2 (en) 2003-01-28 2010-10-12 Proscan Rx Pharma Prostate cancer diagnosis and treatment
EP1444990A1 (en) * 2003-02-07 2004-08-11 Amersham plc Improved Radiometal Complex Compositions
WO2004080412A2 (en) 2003-03-07 2004-09-23 The University Of Toledo Paclitaxel hybrid derivatives
US7638122B2 (en) 2003-03-07 2009-12-29 University Of South Florida Stat3 antagonists and their use as vaccines against cancer
US20070179100A1 (en) 2003-04-09 2007-08-02 Muthiah Manoharan Protected monomers
CA2522637C (en) 2003-04-17 2014-01-21 Alnylam Pharmaceuticals, Inc. Modified irna agents
EP1641742A4 (en) 2003-05-01 2006-11-29 Nst Neurosurvival Technologies COMPOUNDS BINDING SELECTIVELY TO MEMBRANES OF APOPTOTIC CELLS
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US7172751B2 (en) 2003-06-13 2007-02-06 Immunomedics, Inc. D-amino acid peptides
US7232805B2 (en) * 2003-09-10 2007-06-19 Inflabloc Pharmaceuticals, Inc. Cobalamin conjugates for anti-tumor therapy
US20050255042A1 (en) 2003-11-24 2005-11-17 The Regents Of The University Of California Office Of Technology Transfer, University Of California On-demand cleavable linkers for radioconjugates for cancer imaging and therapy
FR2864546A1 (fr) 2003-12-24 2005-07-01 Assist Publ Hopitaux De Paris Methode d'identification et de preparation de lymphocytes t regulateurs/suppresseurs, compositions et utilisations
WO2006051531A2 (en) 2004-11-09 2006-05-18 Spectrum Dynamics Llc Radioimaging
US8586932B2 (en) 2004-11-09 2013-11-19 Spectrum Dynamics Llc System and method for radioactive emission measurement
WO2007010534A2 (en) 2005-07-19 2007-01-25 Spectrum Dynamics Llc Imaging protocols
DE102004004787A1 (de) 2004-01-30 2005-08-18 Schering Ag Neue Effektor-Konjugate, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
AU2005216251B2 (en) 2004-02-23 2011-03-10 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
WO2005094882A1 (en) 2004-03-03 2005-10-13 Millennium Pharmaceuticals, Inc. Modified antibodies to prostate-specific membrane antigen and uses thereof
CN1926433A (zh) 2004-03-03 2007-03-07 拜奥默里克斯公司 用于检测psa的可活化游离形式的方法及其用于诊断前列腺的良性病理学和前列腺的腺癌的用途
DE602005008497D1 (de) 2004-03-15 2008-09-11 Roche Diagnostics Gmbh Verwendung des BNP-Art und ANP-Art Peptiden für das Festsetzen der Gefahren von Herzgefäß- Komplikationen als Folge der Volumenüberlastung
US7910693B2 (en) 2004-04-19 2011-03-22 Proscan Rx Pharma Inc. Prostate cancer diagnosis and treatment
US20060105975A1 (en) 2004-04-19 2006-05-18 Shannon Pendergrast Aptamer-mediated intracellular delivery of therapeutic oligonucleotides
US7691962B2 (en) 2004-05-19 2010-04-06 Medarex, Inc. Chemical linkers and conjugates thereof
US20080008719A1 (en) 2004-07-10 2008-01-10 Bowdish Katherine S Methods and compositions for the treatment of prostate cancer
CN101098854B (zh) 2004-07-23 2012-12-05 恩多塞特公司 二价连接体及其轭合物
DK2213683T3 (da) 2004-08-04 2013-09-02 Mentrik Biotech Llc VARIANT-Fc-REGIONER
KR20070063526A (ko) 2004-08-30 2007-06-19 뉴로메드 파머큐티칼즈 리미티드 칼슘 채널 차단제인 우레아 유도체
US7713944B2 (en) 2004-10-13 2010-05-11 Isis Pharmaceuticals, Inc. Oligomers comprising activated disulfides which bind to plasma proteins and their use for delivery to cells
US7638525B2 (en) 2004-10-27 2009-12-29 Janssen Pharmaceutica N.V. Trisubstituted thiophenes as progesterone receptor modulators
US8423125B2 (en) 2004-11-09 2013-04-16 Spectrum Dynamics Llc Radioimaging
US20060140871A1 (en) 2004-11-30 2006-06-29 Sillerud Laurel O Magnetic resonance imaging of prostate cancer
US7741510B2 (en) 2005-01-13 2010-06-22 E. I. Du Pont De Nemours And Company Rheology control agents
US20060155021A1 (en) 2005-01-13 2006-07-13 Lenges Christian P Coating compositions containing rheology control agents
US7872235B2 (en) 2005-01-13 2011-01-18 Spectrum Dynamics Llc Multi-dimensional image reconstruction and analysis for expert-system diagnosis
EP1846576A4 (en) 2005-02-01 2009-01-07 Us Gov Health & Human Serv BIOMARKERS OF TISSUE STATUS
WO2006093991A1 (en) 2005-03-02 2006-09-08 The Cleveland Clinic Foundation Compounds which bind psma and uses thereof
WO2006096754A2 (en) 2005-03-07 2006-09-14 Archemix Corp. Stabilized aptamers to psma and their use as prostate cancer therapeutics
US8088908B2 (en) 2005-05-10 2012-01-03 City Of Hope Humanized anti-prostate stem cell antigen monoclonal antibody
KR101068612B1 (ko) 2005-05-24 2011-09-30 휴마시스 주식회사 유사구조 단백질 비율 측정을 이용한 진단장치
PT1912677E (pt) 2005-06-20 2013-12-23 Psma Dev Company L L C Conjugados de anticorpos contra psma-fármaco
WO2007006041A2 (en) 2005-07-05 2007-01-11 Purdue Research Foundation Imaging and therapeutic method using monocytes
US20070010014A1 (en) 2005-07-06 2007-01-11 General Electric Company Compositions and methods for enhanced delivery to target sites
EP2374480A3 (en) 2005-08-19 2013-05-01 Endocyte, Inc. Mutli-drug ligand conjugates
EP2015781A4 (en) 2005-09-12 2009-12-23 Univ Johns Hopkins COMPOSITIONS HAVING ANTIANGIOGENIC ACTIVITY AND USES THEREOF
JP5368099B2 (ja) 2005-10-07 2013-12-18 ゲルベ ガリウムと錯体形成することが可能なシグナル部分にカップリングされた、生物学的標的の認識のための部分を含んでなる化合物
CA2670355A1 (en) 2005-11-21 2008-04-24 Medivas, Llc Polymer particles for delivery of macromolecules and methods of use
DK2963011T3 (en) 2005-11-23 2018-08-06 Ventana Med Syst Inc MOLECULAR CONJUGATE
US8258256B2 (en) 2006-01-05 2012-09-04 The Johns Hopkins University Compositions and methods for the treatment of cancer
US7635682B2 (en) 2006-01-06 2009-12-22 Genspera, Inc. Tumor activated prodrugs
PL1999136T3 (pl) 2006-03-14 2013-03-29 Cancer Targeted Tech Llc Peptydomimetyczne inhibitory PSMA, związki je zawierające i sposoby ich zastosowania
CA2646329C (en) 2006-03-20 2018-07-03 The Regents Of The University Of California Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting
US20070225213A1 (en) 2006-03-23 2007-09-27 Kosak Matthew K Nucleic acid carriers for delivery of therapeutic agents
CA2648099C (en) 2006-03-31 2012-05-29 The Brigham And Women's Hospital, Inc System for targeted delivery of therapeutic agents
US20140314864A1 (en) 2006-03-31 2014-10-23 Massachusetts Institute Of Technology System for Targeted Delivery of Therapeutic Agents
CN101557995A (zh) * 2006-07-31 2009-10-14 拜耳消费者保健股份公司 具有用于切割器的可铰接致动器的分体式器皿
EP2087337A4 (en) 2006-11-03 2010-09-08 Purdue Research Foundation METHOD AND DEVICE FOR EX-VIVO FLOW CYTOMETRY
PT2097111E (pt) 2006-11-08 2015-11-03 Molecular Insight Pharm Inc Heterodímeros de ácido glutámico
AU2007328207A1 (en) 2006-12-05 2008-06-12 Landec Corporation Drug delivery
WO2008085828A2 (en) 2007-01-03 2008-07-17 The Johns Hopkins University Peptide modulators of angiogenesis and use thereof
CA2675202C (en) 2007-01-11 2014-09-16 Immunomedics, Inc. Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
WO2008094254A2 (en) 2007-01-26 2008-08-07 City Of Hope Methods and compositions for the treatment of cancer or other diseases
CA2677792C (en) 2007-02-07 2015-04-14 Purdue Research Foundation Positron emission tomography imaging method
WO2008101231A2 (en) 2007-02-16 2008-08-21 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
NZ599239A (en) * 2007-03-14 2013-10-25 Endocyte Inc Binding ligand linked drug delivery conjugates of tubulysins
JP2010524856A (ja) 2007-04-10 2010-07-22 ザ・ジョンズ・ホプキンス・ユニバーシティー ウイルス関連腫瘍の画像化および治療
US9138484B2 (en) 2007-06-25 2015-09-22 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
CA2694266C (en) 2007-06-26 2016-06-14 The Johns Hopkins University Labeled inhibitors of prostate specific membrane antigen (psma), biological evaluation, and use as imaging agents
GB0723246D0 (en) 2007-07-03 2008-01-09 Barton Michelle p53 modulator
JP2010533649A (ja) 2007-07-13 2010-10-28 ザ ジョンズ ホプキンス ユニバーシティー Ｂ７−ｄｃ改変体
KR20100063048A (ko) 2007-07-31 2010-06-10 더 존스 홉킨스 유니버시티 신생물성 또는 감염성 장애의 면역예방 또는 면역치료를 위한 폴리펩티드-핵산 접합체
PL2187965T3 (pl) 2007-08-17 2020-05-18 Purdue Research Foundation Koniugaty wiążący psma ligand-łącznik i sposoby ich zastosowania
US9187521B2 (en) 2007-10-25 2015-11-17 Endocyte, Inc. Tubulysins and processes for preparing
US8450290B2 (en) 2007-11-26 2013-05-28 Enzon Pharmaceuticals, Inc. Methods for treating androgen receptor dependent disorders including cancers
WO2009070302A1 (en) 2007-11-30 2009-06-04 The Johns Hopkins University Prostate specific membrane antigen (psma) targeted nanoparticles for therapy of prostate cancer
EP2231194B1 (en) 2007-12-04 2017-02-22 Alnylam Pharmaceuticals Inc. Folate-irna conjugates
US20090180951A1 (en) 2007-12-12 2009-07-16 Molecular Insight Pharmaceuticals, Inc. Inhibitors of integrin vla-4
BRPI0906797A2 (pt) 2008-01-09 2015-07-14 Molecular Insight Pharm Inc Inibidores de anidrase carbônica ix
ITTO20080313A1 (it) 2008-04-22 2009-10-23 Marco Colombatti Anticorpo monoclonale isolato o suo frammento legante l'antigene specifico di membrana della prostata, suoi coniugati e suoi usi
EP2990487A1 (en) 2008-05-08 2016-03-02 Asuragen, INC. Compositions and methods related to mirna modulation of neovascularization or angiogenesis
DK2291659T3 (en) 2008-05-13 2015-12-21 Univ Yale SMALL CHEMICAL MOLECULES FOR RECRUITING ANTIBODIES TO CANCER CELLS
US8852630B2 (en) 2008-05-13 2014-10-07 Yale University Chimeric small molecules for the recruitment of antibodies to cancer cells
DK2774608T3 (da) * 2008-06-16 2020-01-13 Pfizer Lægemiddelladede polymere nanopartikler og fremgangsmåder til fremstilling og anvendelse deraf
DK3222615T3 (da) 2008-08-01 2022-06-20 Univ Johns Hopkins Psma-bindende stoffer og anvendelser deraf
WO2010027641A2 (en) 2008-08-15 2010-03-11 Georgetown University Na channels, disease, and related assays and compositions
PL2326350T3 (pl) 2008-09-08 2014-03-31 Psma Dev Company L L C Związki do zabijania eksprymujących PSMA, opornych na taksan komórek rakowych
EP2166021A1 (en) 2008-09-16 2010-03-24 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
AU2009293140A1 (en) 2008-09-17 2010-03-25 Endocyte, Inc. Folate receptor binding conjugates of antifolates
US20110288152A1 (en) 2008-10-17 2011-11-24 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
RU2539584C2 (ru) * 2008-12-05 2015-01-20 Моликьюлар Инсайт Фармасьютикалз, Инк. Комплексы технеция и рения с бис(гетероарилами) и способы их применения
WO2010065906A2 (en) 2008-12-05 2010-06-10 Molecular Insight Pharmaceuticals, Inc. Ca-ix specific radiopharmaceuticals for the treatment and imaging of cancer
WO2010065899A2 (en) 2008-12-05 2010-06-10 Molecular Insight Pharmaceuticals, Inc. Technetium-and rhenium-bis(heteroaryl)complexes and methods of use thereof
US10517969B2 (en) 2009-02-17 2019-12-31 Cornell University Methods and kits for diagnosis of cancer and prediction of therapeutic value
US8772226B2 (en) 2009-03-17 2014-07-08 The Johns Hopkins University Methods and compositions for the detection of cancer
PL3964502T3 (pl) 2009-03-19 2024-10-28 The Johns Hopkins University Związki do kierunkowania w psma i ich zastosowania
BR112012000209B8 (pt) 2009-06-15 2021-07-27 Molecular Insight Pharm Inc heterodímeros de ácido glutâmico e seus processos de preparação
WO2011014821A1 (en) 2009-07-31 2011-02-03 Endocyte, Inc. Folate-targeted diagnostics and treatment
US8394922B2 (en) 2009-08-03 2013-03-12 Medarex, Inc. Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof
US8685891B2 (en) 2009-08-27 2014-04-01 Nuclea Biotechnologies, Inc. Method and assay for determining FAS expression
EP2506876B1 (en) 2009-12-02 2016-10-12 Imaginab, Inc. J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use
US8357401B2 (en) 2009-12-11 2013-01-22 Bind Biosciences, Inc. Stable formulations for lyophilizing therapeutic particles
MX338831B (es) 2010-02-04 2016-05-03 Radius Health Inc Moduladores selectivos de receptores de androgenos.
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
US20120322741A1 (en) 2010-02-25 2012-12-20 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
CN101863924B (zh) 2010-05-17 2012-06-27 北京师范大学 99mTc标记肼基烟酰胺基-二氧辛酰-叶酸配合物及制备方法
CA2807511A1 (en) 2010-08-06 2012-02-09 Endocyte, Inc. Processes for preparing tubulysins
KR101236142B1 (ko) 2010-09-30 2013-02-21 경북대학교 산학협력단 가돌리늄 착물을 함유하는 ｍｒｉ조영제
WO2012078534A1 (en) 2010-12-06 2012-06-14 Molecular Insight Pharmaceuticals Psma-targeted dendrimers
WO2012166923A2 (en) 2011-05-31 2012-12-06 Bind Biosciences Drug loaded polymeric nanoparticles and methods of making and using same
PL2739316T3 (pl) 2011-08-05 2019-09-30 Molecular Insight Pharmaceuticals, Inc. Radioznakowane inhibitory antygenu błonowego specyficznego dla prostaty
WO2013028664A1 (en) 2011-08-22 2013-02-28 Siemens Medical Solutions Usa, Inc. Psma imaging agents
US9629918B2 (en) 2012-02-29 2017-04-25 Purdue Research Foundation Folate receptor alpha binding ligands
US20140080175A1 (en) 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
US20140107316A1 (en) 2012-10-16 2014-04-17 Endocyte, Inc. Drug delivery conjugates containing unnatural amino acids and methods for using
US9662402B2 (en) 2012-10-16 2017-05-30 Endocyte, Inc. Drug delivery conjugates containing unnatural amino acids and methods for using
KR102575825B1 (ko) 2012-11-15 2023-09-06 엔도사이트, 인코포레이티드 Psma 발현 세포에 의해 야기되는 질병을 치료하기 위한 컨쥬게이트
US20140154702A1 (en) 2012-11-30 2014-06-05 Endocyte, Inc. Methods For Treating Cancer Using Combination Therapies
CN105246894A (zh) 2012-12-21 2016-01-13 斯皮罗根有限公司 用于治疗增殖性和自身免疫疾病的非对称吡咯并苯并二氮杂卓二聚物
US20140187501A1 (en) 2012-12-28 2014-07-03 Blend Therapeutics, Inc. Targeted Conjugates Encapsulated in Particles and Formulations Thereof
US9889199B2 (en) 2013-02-15 2018-02-13 Case Western Reserve University PSMA ligands and uses thereof
US20140249315A1 (en) 2013-03-01 2014-09-04 Endocyte, Inc. Processes for preparing tubulysins
US10406246B2 (en) 2013-10-17 2019-09-10 Deutsches Kresbsforschungszentrum Double-labeled probe for molecular imaging and use thereof
MY194484A (en) 2013-10-18 2022-11-30 Deutsches Krebsforsch Labeled Inhibitors of Prostate Specific Membrane Antigen (PSMA), Their use as Imaging Agents and Pharmaceutical Agents for the Treatment of Prostate Cancer
WO2015057250A1 (en) 2013-10-18 2015-04-23 Psma Development Company, Llc Combination therapies with psma ligand conjugates
MX2016006219A (es) 2013-11-14 2016-10-28 Endocyte Inc Compuestos para tomografia por emision de positrones.
ES2743482T3 (es) 2014-05-06 2020-02-19 Univ Johns Hopkins Inhibidores de PSMA marcados con metal/radiometal para obtención de imágenes dirigidas a PSMA y radioterapia
EP2993171A1 (en) 2014-09-04 2016-03-09 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Method for the production of 18F-labeled PSMA-specific PET-tracers
EP3183236B1 (en) 2014-08-24 2022-04-20 Max-Planck-Gesellschaft zur Förderung der Wissenschaften Method for the production of 18f-labeled active esters and their application exemplified by the preparation of a psma-specific pet-tracer
AU2015315465B2 (en) 2014-09-08 2019-08-29 Molecular Insight Pharmaceuticals, Inc. Organ protection in PSMA-targeted radionuclide therapy of prostate cancer
US20210323985A1 (en) * 2018-09-21 2021-10-21 Endocyte, Inc. Shielding agents and their use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008121949A1 (en) * 2007-03-30 2008-10-09 Bind Biosciences, Inc. Cancer cell targeting using nanoparticles

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GURMEET KAUR ET AL.: "Biological evaluation of tubulysin A: a potential anticancer and antiangiogenic natural product", 《BIOCHEM J.》 *
MATTHIAS EDER ET AL.: "68Ga-Complex Lipophilicity and the Targeting Property of a Urea-Based PSMA Inhibitor for PET Imaging", 《 BIOCONJUGATE CHEM.》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109312004A (zh) * 2016-06-22 2019-02-05 德克斯特克医疗公司 包含赖氨酸-脲-谷氨酸药效团的改性右旋糖酐缀合物
CN112004812A (zh) * 2018-03-30 2020-11-27 未来化学株式会社 用于前列腺癌的诊断和治疗的psma靶向的放射性药物
CN112004812B (zh) * 2018-03-30 2023-05-26 未来化学株式会社 用于前列腺癌的诊断和治疗的psma靶向的放射性药物

Also Published As

Publication number Publication date
KR102575825B1 (ko) 2023-09-06
AU2025204626B2 (en) 2025-08-28
US20180271991A1 (en) 2018-09-27
US9636413B2 (en) 2017-05-02
US20180256735A1 (en) 2018-09-13
US10912840B2 (en) 2021-02-09
IL238784A0 (en) 2015-06-30
EP3875082A1 (en) 2021-09-08
AU2025204626A1 (en) 2025-07-10
US20250170253A1 (en) 2025-05-29
KR102499944B1 (ko) 2023-02-14
EA201890915A1 (ru) 2018-09-28
ZA201504234B (en) 2016-11-30
AU2022201341A1 (en) 2022-03-24
AU2020201329B2 (en) 2022-02-24
EP3858341A1 (en) 2021-08-04
KR20210041632A (ko) 2021-04-15
TW201420119A (zh) 2014-06-01
US20220265841A1 (en) 2022-08-25
JP2016506372A (ja) 2016-03-03
US20170258932A1 (en) 2017-09-14
AU2013344778B2 (en) 2018-03-22
US20190314515A1 (en) 2019-10-17
TWI674111B (zh) 2019-10-11
JP6892218B2 (ja) 2021-06-23
KR102354613B1 (ko) 2022-01-21
US20180289826A1 (en) 2018-10-11
KR20210041633A (ko) 2021-04-15
AU2020202904A1 (en) 2020-05-21
EP2919774A4 (en) 2016-11-09
MX2021003858A (es) 2021-04-28
EA201590783A1 (ru) 2015-11-30
US20160361376A1 (en) 2016-12-15
AU2020202904B2 (en) 2022-02-24
JP2021073272A (ja) 2021-05-13
HK1255308A1 (zh) 2019-08-16
US20180256736A1 (en) 2018-09-13
AU2020201329A1 (en) 2020-03-12
EP2919774A1 (en) 2015-09-23
AU2013344778C1 (en) 2024-06-27
MY171561A (en) 2019-10-18
HK1211493A1 (en) 2016-05-27
AU2013344778A1 (en) 2015-05-21
BR112015011118A2 (pt) 2017-07-11
US20210154311A1 (en) 2021-05-27
AU2020201329C1 (en) 2024-05-09
SG10201706618UA (en) 2017-09-28
CN108042811A (zh) 2018-05-18
MX2015006109A (es) 2016-02-05
US20180256737A1 (en) 2018-09-13
AU2018204504A1 (en) 2018-07-12
KR20220013456A (ko) 2022-02-04
JP2019081778A (ja) 2019-05-30
CA2891476A1 (en) 2014-05-22
SG11201503303TA (en) 2015-06-29
US20160361433A1 (en) 2016-12-15
CA2891476C (en) 2022-07-05
US20160361432A1 (en) 2016-12-15
KR102318999B1 (ko) 2021-10-29
CA3158675A1 (en) 2014-05-22
WO2014078484A1 (en) 2014-05-22
US20210154312A1 (en) 2021-05-27
BR112015011118B1 (pt) 2022-12-13
KR20150104092A (ko) 2015-09-14
US9782493B2 (en) 2017-10-10
US20180256734A1 (en) 2018-09-13
US20150297735A1 (en) 2015-10-22
US20180256733A1 (en) 2018-09-13
AU2024203858A1 (en) 2024-06-27
KR20230025942A (ko) 2023-02-23
JP2023098946A (ja) 2023-07-11

Similar Documents

Publication Publication Date Title
US20250170253A1 (en) Conjugates for treating diseases caused by psma expressing cells
JP2016506372A5 (enExample)
HK40058595A (en) Psma ligand-containing conjugates for the treatment of prostate cancer
HK40059888A (en) Conjugates for treating diseases caused by psma expressing cells
EA041296B1 (ru) Конъюгаты для доставки лекарственных средств и способы лечения заболеваний, вызванных клетками, экспрессирующими psma

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1211493

Country of ref document: HK

WW01 Invention patent application withdrawn after publication
WW01 Invention patent application withdrawn after publication

Application publication date: 20150722

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1211493

Country of ref document: HK